{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:23:12Z","timestamp":1789593792502,"version":"build-2803163510"},"reference-count":127,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pancreatic cancer is a leading cause of cancer-related mortality, and unfortunately, the prognosis for this stubborn tumor type has remained bleak for an extended period. Current treatment options are limited and often ineffective, highlighting the need for innovative therapeutic strategies. Research in tumor immunotherapy has advanced significantly over the past few decades, leading to numerous studies progressing to clinical evaluation. Cancer vaccines are regarded as a promising therapeutic approach for treating pancreatic cancers. Cancer vaccines offer distinct advantages, especially for patients who are unresponsive to other treatments, as they can elicit broad and long-lasting T cell responses. This review offers a thorough examination of recent preclinical and clinical results of therapeutic cancer vaccines in pancreatic cancer therapy, highlighting the recent advancements in vaccine delivery platforms. Despite ongoing clinical efforts to develop cancer vaccines, there has not been a breakthrough in clinical outcomes, primarily due to substantial challenges including the low mutation burdens, the assessment of immune responses in preclinical models, and the intrinsic resistances to cancer vaccines. By tackling these challenges, cancer vaccines can expand the possibilities of personalized immunotherapy for pancreatic cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1674743","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T05:23:26Z","timestamp":1760937806000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic cancer vaccines in pancreatic cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"YuHan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShengJin","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","article-title":"Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors","volume":"18","author":"Klein","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","first-page":"C540","DOI":"10.1152\/ajpcell.00331.2022","article-title":"Barriers and opportunities for gemcitabine in pancreatic cancer therapy","volume":"324","author":"Beutel","year":"2023","journal-title":"Am J Physiol Cell Physiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-22-2045","article-title":"Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer","volume":"83","author":"Park","year":"2023","journal-title":"Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvsm.2023.12.002","article-title":"Cancer Immunotherapy","volume":"54","author":"Bergman","year":"2024","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"B8","doi-asserted-by":"publisher","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: State of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci Adv"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00539-6","article-title":"Cellular networks controlling T cell persistence in adoptive cell therapy","volume":"21","author":"Chan","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-3145","article-title":"Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy","volume":"28","author":"Li","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2025.115671","article-title":"Classic versus innovative strategies for immuno-therapy in pancreatic cancer","volume":"225","author":"Formelli","year":"2025","journal-title":"Adv Drug Delivery Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17040589","article-title":"Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies","volume":"17","author":"Sherpally","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252111560","article-title":"Advancing Immunotherapy in Pancreatic Cancer","volume":"25","author":"Hegazi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102301","article-title":"Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer","volume":"6","author":"Aznar","year":"2025","journal-title":"Cell Rep Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7827","DOI":"10.1038\/s41467-025-63146-2","article-title":"Targeting spermine metabolism to overcome immunotherapy resistance in pancreatic cancer","volume":"16","author":"Yang","year":"2025","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-24-1712","article-title":"The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer","volume":"15","author":"Xie","year":"2025","journal-title":"Cancer Discovery"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107867","article-title":"RAE1-armoured DC vaccine boosts NKG2D-CAR-T cells elicited anti-solid tumour treatment","volume":"219","author":"Duan","year":"2025","journal-title":"Pharmacol Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01316-4","article-title":"Eliciting antitumor immunity via therapeutic cancer vaccines","author":"Peng","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-2025-233","article-title":"Identification of esophageal cancer tumor antigens and immune subtypes for guiding vaccine development","volume":"17","author":"Liu","year":"2025","journal-title":"J Thorac Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673348041250407062346","article-title":"Identification and Experimental Validation of Tumor Antigens and Hypoxia Subtypes of Osteosarcoma for Potential mRNA Vaccine Development","author":"Ren","year":"2025","journal-title":"Curr Med Chem"},{"key":"B22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s00262-025-04107-y","article-title":"Neo-antigen specific cancer vaccines for acute lymphoblastic leukemia-challenges, opportunities, and future directions","volume":"74","author":"Sandstad","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent advances in therapeutic cancer vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00707-2","article-title":"A guide to antigen processing and presentation","volume":"22","author":"Pishesha","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.04.017","article-title":"Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming","volume":"25","author":"Allan","year":"2006","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104813","article-title":"Unlock the code of MHC II-enabled Cancer immunotherapy","volume":"214","author":"Liu","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaci.2022.10.011","article-title":"From thymus to tissues and tumors: A\u2002review of T-cell biology","volume":"151","author":"Chopp","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27782","article-title":"CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review","volume":"234","author":"Farhood","year":"2019","journal-title":"J Cell Physiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1609162","article-title":"Peptide based vesicles for cancer immunotherapy: design, construction and applications","volume":"16","author":"Yu","year":"2025","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2535787","article-title":"Natural carrier systems in cancer vaccines and immunotherapy","volume":"21","author":"Owliaee","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2323256","article-title":"Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis","volume":"20","author":"Tiwari","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines3020344","article-title":"Whole Tumor Antigen Vaccines: Where Are We","volume":"3","author":"Chiang","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1586892","article-title":"Dendritic cell-derived exosomes as anti-cancer cell-free agents: new insights into enhancing immunogenic effects","volume":"16","author":"Redkin","year":"2025","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13046-020-01781-x","article-title":"Dexosomes as a cell-free vaccine for cancer immunotherapy","volume":"39","author":"Nikfarjam","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.trsl.2015.07.008","article-title":"Antitumor dendritic cell-based vaccines: lessons from 20\u2002years of clinical trials and future perspectives","volume":"168","author":"Constantino","year":"2016","journal-title":"Transl Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147509","article-title":"Enhancing Dendritic Cell Cancer Vaccination: The Synergy of Immune Checkpoint Inhibitors in Combined Therapies","volume":"25","author":"Zanotta","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B38","article-title":"Significance of Wilms' tumor 1 antigen as a cancer vaccine for pancreatic cancer","volume":"24","author":"Koido","year":"2017","journal-title":"Discovery Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e958950","DOI":"10.4161\/21624011.2014.958950","article-title":"Chemoimmunotherapy targeting Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer","volume":"3","author":"Koido","year":"2014","journal-title":"Oncoimmunology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000020","article-title":"Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer","volume":"37","author":"Nishida","year":"2014","journal-title":"J Immunother"},{"key":"B41","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13063-019-3332-5","article-title":"A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy","volume":"20","author":"Katsuda","year":"2019","journal-title":"Trials"},{"key":"B42","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/cas.12621","article-title":"Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer","volume":"106","author":"Mayanagi","year":"2015","journal-title":"Cancer Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.13659","article-title":"Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single-center phase I\/II trial","volume":"25","author":"Ogasawara","year":"2021","journal-title":"Ther Apher Dial"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12464","article-title":"WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study","volume":"38","author":"Yanagisawa","year":"2018","journal-title":"Anticancer Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/21645515.2018.1524238","article-title":"Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines","volume":"15","author":"Hanada","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009765","article-title":"Dendritic cells pulsed with multifunctional Wilms' tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer","volume":"12","author":"Koido","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011426","article-title":"Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms' tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine","volume":"13","author":"Koido","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e2315509121","DOI":"10.1073\/pnas.2315509121","article-title":"The MUC1-HIF-1\u03b1 signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling","volume":"121","author":"Murthy","year":"2024","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B49","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ccell.2017.06.004","article-title":"MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer","volume":"32","author":"Shukla","year":"2017","journal-title":"Cancer Cell"},{"key":"B50","article-title":"A phase I\/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors","volume":"6","author":"Lepisto","year":"2008","journal-title":"Cancer Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-002-0317-z","article-title":"Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I\/II clinical trial","volume":"51","author":"Pecher","year":"2002","journal-title":"Cancer Immunol Immunother"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10071092","article-title":"A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice","volume":"10","author":"Pan","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14593","article-title":"Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I\/IIa Clinical Trial","volume":"40","author":"Nagai","year":"2020","journal-title":"Anticancer Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","article-title":"mRNA therapeutics in cancer immunotherapy","volume":"20","author":"Beck","year":"2021","journal-title":"Mol Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.7150\/thno.77350","article-title":"Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"key":"B56","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00262-024-03924-x","article-title":"CircRNA-loaded DC vaccine in combination with low-dose gemcitabine induced potent anti-tumor immunity in pancreatic cancer model","volume":"74","author":"Cai","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02327-6","article-title":"Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response","volume":"129","author":"P\u00e9rez-Ba\u00f1os","year":"2023","journal-title":"Br J Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11605-012-2064-6","article-title":"Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study","volume":"17","author":"Hardacre","year":"2013","journal-title":"J Gastrointest Surg"},{"key":"B59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/sla.0000000000004669","article-title":"A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer","volume":"275","author":"Hewitt","year":"2022","journal-title":"Ann Surg"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2001.19.1.145","article-title":"Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation","volume":"19","author":"Jaffee","year":"2001","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31829fb7a2","article-title":"Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer","volume":"36","author":"Le","year":"2013","journal-title":"J Immunother"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-07-0371","article-title":"Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation","volume":"14","author":"Laheru","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1038\/s41467-023-39196-9","article-title":"A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma","volume":"14","author":"Heumann","year":"2023","journal-title":"Nat Commun"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.10.039","article-title":"Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal Adenocarcinoma","volume":"121","author":"Hill","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-1395","article-title":"A Virus-Infected, Reprogrammed Somatic Cell-Derived Tumor Cell (VIReST) Vaccination Regime Can Prevent Initiation and Progression of Pancreatic Cancer","volume":"26","author":"Lu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-024-01102-w","article-title":"Advances in nucleic acid-based cancer vaccines","volume":"32","author":"Liao","year":"2025","journal-title":"J BioMed Sci"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-023-00821-z","article-title":"Coding Therapeutic Nucleic Acids from Recombinant Proteins to Next-Generation Vaccines: Current Uses, Limitations, and Future Horizons","volume":"66","author":"Harisa","year":"2024","journal-title":"Mol Biotechnol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102261","article-title":"ENO1 promotes PDAC progression by inhibiting CD8(+) T cell infiltration through upregulating PD-L1 expression via HIF-1\u03b1 signaling","volume":"52","author":"Aziguli","year":"2025","journal-title":"Transl Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0385-8","article-title":"Alpha-enolase (ENO1) controls alpha v\/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis","volume":"10","author":"Principe","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e1112940","DOI":"10.1080\/2162402x.2015.1112940","article-title":"Anti-\u03b1-enolase antibody limits the invasion of myeloid-derived suppressor cells and attenuates their restraining effector T cell response","volume":"5","author":"Cappello","year":"2016","journal-title":"Oncoimmunology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.01.020","article-title":"Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer","volume":"144","author":"Cappello","year":"2013","journal-title":"Gastroenterology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-15-1346","article-title":"Macrophage PI3K\u03b3 Drives Pancreatic Ductal Adenocarcinoma Progression","volume":"6","author":"Kaneda","year":"2016","journal-title":"Cancer Discovery"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10020051","article-title":"Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners","volume":"10","author":"Cappello","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B74","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13046-024-03080-1","article-title":"PI3K\u03b3 inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer","volume":"43","author":"Curcio","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001071","article-title":"In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination","volume":"8","author":"Mandili","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1159\/000055905","article-title":"Expression spectrum and methylation-dependent regulation of melanoma antigen-encoding gene family members in pancreatic cancer cells","volume":"2","author":"Bert","year":"2002","journal-title":"Pancreatology"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2012.05.031","article-title":"Targeting the MAGE A3 antigen in pancreatic cancer","volume":"152","author":"Cogdill","year":"2012","journal-title":"Surgery"},{"key":"B78","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1186\/s12967-023-04519-3","article-title":"Immunization with a multi-antigen targeted DNA vaccine eliminates chemoresistant pancreatic cancer by disrupting tumor-stromal cell crosstalk","volume":"21","author":"Qin","year":"2023","journal-title":"J Transl Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.07.008","article-title":"CAFs\/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer","volume":"26","author":"Geng","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-191","article-title":"Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine","volume":"9","author":"Rong","year":"2009","journal-title":"BMC Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-010-0845-4","article-title":"Induction of antigen-specific CTL and antibody responses in mice by a novel recombinant tandem repeat DNA vaccine targeting at mucin 1 of pancreatic cancer","volume":"136","author":"Wu","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1506632","article-title":"and IL-21-armed oncolytic vaccinia virus significantly enhances anti-tumor activity and synergizes with anti-PD1 immunotherapy in pancreatic cancer","volume":"15","author":"Xuan","year":"2024","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat Rev Genet"},{"key":"B84","article-title":"DNA vaccines forum: how to enhance DNA vaccines safety and potency","volume":"8","author":"Ulmer","year":"2005","journal-title":"IDrugs"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.05.005","article-title":"RNA vaccines for cancer: Principles to practice","volume":"42","author":"Guasp","year":"2024","journal-title":"Cancer Cell"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1029069","article-title":"mRNA vaccines for cancer immunotherapy","volume":"13","author":"Vishweshwaraiah","year":"2022","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.146204","article-title":"mRNA vaccines: Emerging opportunities for herpesvirus prevention and therapeutic intervention","volume":"321","author":"Cai","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-CT169","article-title":"Abstract CT169: A phase Ia study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in patients with locally advanced or metastatic solid tumors","volume":"80","author":"Braiteh","year":"2020","journal-title":"Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer","volume":"2025","author":"Sethna","year":"8056","journal-title":"Nature"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1517\/13543780902897631","article-title":"Cancer vaccination with telomerase peptide GV1001","volume":"18","author":"Kyte","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"B92","article-title":"GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers","volume":"9","author":"Nava-Parada","year":"2007","journal-title":"Curr Opin Mol Ther"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603437","article-title":"Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I\/II study","volume":"95","author":"Bernhardt","year":"2006","journal-title":"Br J Cancer"},{"key":"B94","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41416-023-02474-w","article-title":"Efficacy of GV1001 with gemcitabine\/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4\/2015): an open-label, randomised, Phase 3 trial","volume":"130","author":"Jo","year":"2024","journal-title":"Br J Cancer"},{"key":"B95","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13046-017-0509-1","article-title":"Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer","volume":"36","author":"Shindo","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"e2407976","DOI":"10.1002\/advs.202407976","article-title":"Targeting Mesothelin Enhances Personalized Neoantigen Vaccine Induced Antitumor Immune Response in Orthotopic Pancreatic Cancer Mouse Models","volume":"12","author":"Cai","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005491","article-title":"TGF\u03b2-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer","volume":"10","author":"Perez-Penco","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.2023.J109","article-title":"Vasohibin-2-Targeting Therapies for the Treatment of Pancreatic Ductal Adenocarcinoma","volume":"262","author":"Suzuki","year":"2024","journal-title":"Tohoku J Exp Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S186606","article-title":"A peptide-CpG-DNA-liposome complex vaccine targeting TM4SF5 suppresses growth of pancreatic cancer in a mouse allograft model","volume":"11","author":"Park","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results","author":"Wainberg","year":"2025","journal-title":"Nat Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.07.023","article-title":"Enhancing pancreatic cancer immunotherapy: Leveraging localized delivery strategies through the use of implantable devices and scaffolds","volume":"373","author":"Minaei","year":"2024","journal-title":"J Control Release"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217350","article-title":"Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy","volume":"610","author":"Yu","year":"2025","journal-title":"Cancer Lett"},{"key":"B104","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and Opportunities for Pancreatic Cancer Immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biodatasci-092820-112713","article-title":"Neoantigen Controversies","volume":"4","author":"Castro","year":"2021","journal-title":"Annu Rev BioMed Data Sci"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00210-y","article-title":"Targeting public neoantigens for cancer immunotherapy","volume":"2","author":"Pearlman","year":"2021","journal-title":"Nat Cancer"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.06.019","article-title":"A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma","author":"Blass","year":"2025","journal-title":"Cell"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: Advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2025.103913","article-title":"Scale-up and cGMP manufacturing of next-generation vaccine adjuvant saponin\/MPLA nanoParticles (SMNP)","volume":"114","author":"Pallerla","year":"2025","journal-title":"J Pharm Sci"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132091","article-title":"Endoscopic Immuno-Oncology: A New Frontier in Treatment of Pancreatic Cancer","volume":"17","author":"Vemulapalli","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112509","article-title":"Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death","volume":"28","author":"Zhou","year":"2025","journal-title":"iScience"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47050330","article-title":"CRISPR-Cas9 in the Tailoring of Genetically Engineered Animals","volume":"47","author":"Urban","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1126\/science.adu8000","article-title":"Controlled colonization of the human gut with a genetically engineered microbial therapeutic","volume":"389","author":"Whitaker","year":"2025","journal-title":"Science"},{"key":"B115","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12964-024-01711-w","article-title":"Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance","volume":"22","author":"Yang","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.07.004","article-title":"Immune vulnerabilities of mutant KRAS in pancreatic cancer","volume":"9","author":"Cheng","year":"2023","journal-title":"Trends Cancer"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/s1535-6108(03)00309-x","article-title":"Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse","volume":"4","author":"Hingorani","year":"2003","journal-title":"Cancer Cell"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1053\/j.gastro.2021.12.273","article-title":"Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma","volume":"162","author":"Hosein","year":"2022","journal-title":"Gastroenterology"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-23-0825","article-title":"Small Extracellular Vesicle piR-hsa-30937 Derived from Pancreatic Neuroendocrine Neoplasms Upregulates CD276 in Macrophages to Promote Immune Evasion","volume":"12","author":"Zhong","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"e56934","DOI":"10.7759\/cureus.56934","article-title":"WT1 Cancer Vaccine in Advanced Pancreatic Cancer: A Systematic Review","volume":"16","author":"Gugulothu","year":"2024","journal-title":"Cureus"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06183-9","article-title":"Dilemma and Challenge of Immunotherapy for Pancreatic Cancer","volume":"66","author":"Wu","year":"2021","journal-title":"Dig Dis Sci"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3390\/cells12172159","article-title":"Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2022.2120471","article-title":"Combination immunotherapy for pancreatic cancer: challenges and future considerations","volume":"18","author":"G\u00f6ssling","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-024-01078-8","article-title":"The Current Landscape of Clinical Trials for Immunotherapy in Pancreatic Cancer: A State-of-the-Art Review","volume":"55","author":"Sarfraz","year":"2024","journal-title":"J Gastrointest Cancer"},{"key":"B125","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40779-022-00416-w","article-title":"Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine","volume":"9","author":"Huang","year":"2022","journal-title":"Mil Med Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01692-4","article-title":"Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy","volume":"18","author":"Liu","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2025.100353","article-title":"Nanoparticle technologies in precision oncology and personalized vaccine development: Challenges and advances","volume":"10","author":"Imani","year":"2025","journal-title":"Int J Pharm X"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1674743\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T05:23:27Z","timestamp":1760937807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1674743\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":127,"alternative-id":["10.3389\/fimmu.2025.1674743"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1674743","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"article-number":"1674743"}}